Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-09-29
2000-09-19
McKane, Joseph
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514421, 514568, 514574, 548452, 548512, A61K 31192, A61K 31194, A61K 314015, C07D20952
Patent
active
061213063
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to a method of obtaining (1S,4R)-1-azabicyclo[2.2.1]heptan-3-one, the di-p-toluoyl-L-tartaric acid hemisalt of (1S,4R)-1-azabicyclo[2.2.1]heptan-3-one, (1R,4S)-1-azabicyclo[2.2.1]heptan-3-one and the di-p-toluoyl-D-tartaric acid hemisalt of (1R,4S)-1-azabicyclo[2.2.1]heptan-3-one from (.+-.)-1-azabicyclo[2.2.1]heptan-3-one.
BACKGROUND OF THE INVENTION
(.+-.)-1-Azabicyclo[2.2.1]heptan-3-one as well as enantiomerically pure forms of 1-azabicyclo[2.2.1]heptan-3-one and mixtures thereof have been shown to be useful in the preparation of compounds which are useful as pharmaceutical agents. See, e.g., U.S. Pat. No. 5,514,812, incorporated herein by reference. Certain compounds formed from enantiomerically pure forms of 1-azabicyclo[2.2.1]heptan-3-one are muscarinic agonists, rendering them useful as pharmaceutical agents in the area of cognition disorders, as disclosed, for example, in U.S. Pat. No. 5,346,911; European Published Applications EP 414,394 A2; EP 427,390 A2; EP 402,056 A2; EP 307,142 A1; and various publications, e.g. H. Tecle et al., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, 5, 631-636, (1995) ; H. Tecle, et al., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, 5, 637-642, (1995), all incorporated herein by reference.
In order to be commercially viable, an efficient and cost-effective, large scale process for preparing substantially enantiomerically pure forms of 1-azabicyclo[2.2.1]heptan-3-one isomers is needed. Jakob Boelsterli et al., HELV. CHIM. ACTA, 75, 507-12 (1992) prepared (1S,4R)-1-azabicyclo[2.2.1]heptan-3-one by oxidation of (1S,3S,4R)-1-azabicyclo[2.2.1]heptan-3-ol. See also, U.S. Pat. No. 5,346,911. This route involves the formation of racemic 1-azabicyclo[2.2.1]heptan-3-exo-ol in four or more steps. The racemic alcohol is then resolved using D-tartaric acid (unnatural tartaric acid) by formation of a 1 to 1 salt. (1S,3S,4R)-1-azabicyclo[2.2.1]heptan-3-ol is then freed from the D-tartaric acid and recrystallized several times. The (1S,3S,4R)-1-azabicyclo[2.2.1]heptan-3-ol is then oxidized (Swern oxidation) at low temperatures (-60.degree. C.) to give (1S,4R)-1-azabicyclo[2.2.1]heptan-3-one. The crude (1S,4R)-1-azabicyclo[2.2.1]heptan-3-one is then isolated as the hydrochloride salt and recrystallized. A similar reaction sequence is carried out using L-tartaric acid in order to obtain (1R,4S)-1-azabicyclo[2.2.1]heptan-3-one.
Although the route disclosed by the prior art provides (1S,4R)- and (1R,4S)-azabicyclo[2.2.1]heptan-3-ones as the respective hydrochloride salts in high enantiomeric purity, the process is difficult to conduct on large-scale for the following reasons: 1) the process is long, involving at least five steps in addition to the resolution and free alcohol formation steps, 2) the process utilizes a low temperature oxidation step (-60.degree. C.) which requires specialized equipment on a manufacturing scale, and 3) the process relies upon a potentially hazardous oxidation step. In the latter respect, see, e.g., L. Bretherick, "Bretherick's Handbook of Reactive Chemical Hazards", Fourth Edition, Butterworths, Boston, Mass., pp. 299-300 (1990). The known potential alternative to the hazardous oxidation step, utilized in the formation of racemic 1-azabicyclo[2.2.1]heptan-3-one as reported by Spry et al., J. ORG. CHEM, 34, 3674 (1969), does not work as well, and utilizes chromic acid, a toxic and environmentally problematic substance and a known carcinogen. See, e.g., Budavari, S., Ed., THE MERCK INDEX, Twelfth Edition, p. 375, Merck, Whitehouse Station, N.J. (1996). It would be desirable to provide an efficient and economical process for obtaining substantially enantiomerically pure (1S,4R)-1-azabicyclo[2.2.1]heptan-3-one and (1R,4S)-1-azabicyclo[2.2.1]heptan-3-one. It would be further desirable to provide these substantially enantiomerically pure isomers in a stable, easily stored form.
SUMMARY OF THE INVENTION
The present invention provides an efficient means for obtaining (1S,4R)-1-azabicyclo[2.2.1]heptan-3-one, the stable easily
REFERENCES:
patent: 5346911 (1994-09-01), Augelli-Szafran et al.
Boelsterli et al., "39. Absolute Configuration of 3-Substituted 1-Azabicyclo[2.2.1]heptanes," Helvetica Chimica Acta, vol. 75, pp. 507-512, 1992.
Jerry March, Advanced Organic Chemistry, Fourth Edition, p. 108, 1992.
McKane Joseph
Oswecki Jane
Warner-Lambert & Company
LandOfFree
Method of making (1S, 4R)-1-azabicyclo[2.2.1]heptan-3-one and (1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of making (1S, 4R)-1-azabicyclo[2.2.1]heptan-3-one and (1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of making (1S, 4R)-1-azabicyclo[2.2.1]heptan-3-one and (1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073676